{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-005085","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.197224+00:00","generated_at":"2026-06-06T08:18:13.899129+00:00","sec_items":["2.03","3.02","5.01","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AgeX draws $500k note, converts preferred shares giving Juvenescence 75.6% control, extends Serina merger deadline","bullets":["Drew $500,000 under secured convertible note with Juvenescence; repayment due Feb 14, 2024.","Converted 211,600 Series A and 148,400 Series B preferred shares into 50M common shares for Juvenescence.","Juvenescence now holds 66.4M shares (75.6% of outstanding); change in control of AgeX deemed to have occurred.","Merger agreement with Serina extended to April 29, 2024; Juvenescence entered support agreement to vote in favor.","Post-merger, Serina holders expected to own ~75% of combined company; AgeX holders ~25%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-005085","json":"https://secwatch.observer/filing/0001493152-24-005085.json","markdown":"https://secwatch.observer/filing/0001493152-24-005085.md","text":"https://secwatch.observer/filing/0001493152-24-005085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/0001493152-24-005085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:18:13.899129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5976e68451ad9ea6c47e5f3001530f819f87d65","claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On February 1, 2024, AgeX Therapeutics, Inc. (“AgeX”) drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note (as amended, the “Secured Note”) with Juvenescence Limited (“Juvenescence”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/0001493152-24-005085-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Maturity","value":"February 14, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}